News
Vesigen Therapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance (FARA) to Develop a Targeted Genome Editing Therapeutic Strategy
CAMBRIDGE, Mass., March 14, 2023 /Business Wire/ -- Vesigen Therapeutics, Inc., a biotechnology company developing targeted therapies by engineering a ...
Vesigen Therapeutics, Inc. Announces Expansion of Scientific Advisory Board
CAMBRIDGE, Mass., February 7, 2023 /Business Wire/ -- Vesigen Therapeutics, Inc., a biotechnology company developing transformative therapeutics by engineering naturally ...
Vesigen Therapeutics Names Rakhshita Dhar to Board of Directors
CAMBRIDGE, Mass., January 30, 2023 /Business Wire/ -- Vesigen Therapeutics, Inc., a biotechnology company developing transformative therapeutics by engineering naturally ...
Vesigen Therapeutics Appoints Paulash Mohsen as Chief Executive Officer
CAMBRIDGE, Mass., Apr. 11, 2022 /Business Wire/ -- Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery ...
Vesigen Therapeutics Presents at 3rd Exosome-Based Therapeutic Development Summit: Expanding the Therapeutic Boundaries of Exosomes
Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle non-viral delivery technology to develop transformative therapeutics, will be ...
Vesigen Therapeutics Presents Data on Recent Advances to its Engineered ARMMs Therapeutic Delivery Platform at ISEV 2021
Vesigen Therapeutics, Inc., a biotechnology company pioneering development of a novel extracellular vesicle-mediated delivery platform, today announced new data supporting ...
Stay Connected
Vesigen Therapeutics
790 Memorial Drive
Suite 103
Cambridge, MA 02139
